Journal
CLINICAL INFECTIOUS DISEASES
Volume 52, Issue -, Pages S312-S325Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir046
Keywords
-
Categories
Funding
- US Department of Defense [W81XWH-08-1-0477]
- Food and Drug Administration
- Infectious Diseases Society of America
- AstraZeneca Pharmaceuticals
- Bio Merieux, Inc.
- Cepheid
- Gilead Sciences
- Intelligent MDX, Inc.
- Inverness Medical Innovations
- Roche Molecular Systems
- GenProbe/Prodesse
- Luminex Molecular Diagnostics
- Diagnostic Hybrids
- 3M Molecular Diagnostics
Ask authors/readers for more resources
The rapid, sensitive, and specific identification of the microbial etiological characteristics of respiratory tract infections enhances the appropriate use of both antibiotics and antiviral agents and reduces the risk of nosocomial transmission. This article reviews the current nucleic acid amplification tests approved by the U.S. Food and Drug Administration (FDA) for the detection of respiratory pathogens. In addition, Emergency Use Authorization tests for the detection of 2009 influenza A H1N1 are discussed. The advantages and limitations of the current FDA-approved/cleared tests are reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available